RELIANCE 1,300.05 -1.60 (-0.12%) 
HDFCBANK 1,910.35 -6.00 (-0.31%) BAJFINANCE 9,111.20 -186.90 (-2.01%) INFY 1,480.20 +8.90 (0.60%) KOTAKBANK 2,203.00 -21.00 (-0.94%) NESTLEIND 2,414.20 -20.60 (-0.85%) HINDUNILVR 2,331.60 +6.35 (0.27%) BHARTIARTL 1,815.60 -29.20 (-1.58%) DMART 4,373.55 -123.30 (-2.74%) SBIN 798.75 -14.45 (-1.78%) SUNPHARMA 1,786.85 -17.65 (-0.98%) AXISBANK 1,165.30 -42.00 (-3.48%) MARUTI 11,685.90 -214.90 (-1.81%) HDFC 2,729.95 -17.05 (-0.62%) ULTRACEMCO 12,236.20 +73.05 (0.60%) LT 3,272.15 -28.40 (-0.86%) ASIANPAINT 2,430.20 -34.40 (-1.40%) HCLTECH 1,579.30 -7.60 (-0.48%) ICICIBANK 1,404.55 +2.30 (0.16%) ONGC 246.35 -3.00 (-1.20%) WIPRO 240.80 -1.95 (-0.80%) BRITANNIA 5,419.75 -43.80 (-0.80%) BPCL 295.40 -6.55 (-2.17%) ITC 428.15 -1.95 (-0.45%) TITAN 3,362.15 -22.20 (-0.66%) POWERGRID 306.25 -8.05 (-2.56%) HDFCLIFE 705.00 -3.20 (-0.45%) NTPC 356.30 -6.75 (-1.86%) BAJAJFINSV 2,045.35 -60.05 (-2.85%) Download Unicorn Signals App
By EquityPandit
Suven Life Sciences has received a patent from India and Japan both for a drug used in the treatment of neuro-degenerative diseases.
Suven Life in a BSE filing said, it has been granted “one product patent from India and one product patent from Japan corresponding to the New Chemical Entities(NCEs) for the treatment of disorders associated with neurodegenerative diseases.”
According to the company, patents are valid till 2027 and 2032 respectively.
